Clinical group, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
PLoS One. 2013 Jul 19;8(7):e69783. doi: 10.1371/journal.pone.0069783. Print 2013.
Mortality from bacterial meningitis in African adults is significantly higher than those in better resourced settings and adjunctive therapeutic interventions such as dexamethasone and glycerol have been shown to be ineffective. We conducted a study analysing data from clinical trials of bacterial meningitis in Blantyre, Malawi to investigate the clinical parameters associated with this high mortality.
We searched for all clinical trials undertaken in Blantyre investigating bacterial meningitis from 1990 to the current time and combined the data from all included trial datasets into one database. We used logistic regression to relate individual clinical parameters to mortality. Adults with community acquired bacterial meningitis were included if the CSF culture isolate was consistent with meningitis or if the CSF white cell count was >100 cells/mm(3) (>50% neutrophils) in HIV negative participants and >5 cells/mm(3) in HIV positive participants. Outcome was measured by mortality at discharge from hospital (after 10 days of antibiotic therapy) and community follow up (day 40).
Seven hundred and fifteen episodes of bacterial meningitis were evaluated. The mortality rate was 45% at day 10 and 54% at day 40. The most common pathogens were S.pneumoniae (84% of positive CSF isolates) and N.meningitidis (4%). 607/694 (87%) participants tested were HIV antibody positive. Treatment delays within the hospital system were marked. The median presenting GCS was 12/15, 17% had GCS<8 and 44.9% had a seizure during the illness. Coma, seizures, tachycardia and anaemia were all significantly associated with mortality on multivariate analysis. HIV status and pneumococcal culture positivity in the CSF were not associated with mortality. Adults with community acquired bacterial meningitis in Malawi present with a severe clinical phenotype. Predictors of high mortality are different to those seen in Western settings. Optimising in-hospital care and minimising treatment delays presents an opportunity to improve outcomes considerably.
在资源较差的环境中,成人细菌性脑膜炎的死亡率明显高于其他地区,并且已证明辅助治疗干预(如地塞米松和甘油)无效。我们进行了一项研究,分析了马拉维布兰太尔细菌性脑膜炎临床试验的数据,以调查与高死亡率相关的临床参数。
我们搜索了 1990 年至当前时间在布兰太尔进行的所有细菌性脑膜炎临床试验,并将所有纳入试验数据集的数据合并到一个数据库中。我们使用逻辑回归将个体临床参数与死亡率相关联。如果 CSF 培养分离物与脑膜炎一致,或者 HIV 阴性参与者的 CSF 白细胞计数>100 个细胞/mm³(>50%中性粒细胞),或 HIV 阳性参与者的 CSF 白细胞计数>5 个细胞/mm³,则纳入社区获得性细菌性脑膜炎的成年患者。出院时(抗生素治疗 10 天后)和社区随访(第 40 天)的死亡率作为结局进行评估。
共评估了 715 例细菌性脑膜炎发作。第 10 天的死亡率为 45%,第 40 天的死亡率为 54%。最常见的病原体是肺炎链球菌(84%的阳性 CSF 分离株)和脑膜炎奈瑟菌(4%)。694 例患者中有 607 例(87%)检测到 HIV 抗体阳性。医院系统内的治疗延迟非常明显。入院时的中位 GCS 为 12/15,17%的患者 GCS<8,44.9%的患者在发病期间出现抽搐。昏迷、抽搐、心动过速和贫血在多变量分析中均与死亡率显著相关。HIV 状态和 CSF 中的肺炎球菌培养阳性与死亡率无关。马拉维社区获得性细菌性脑膜炎的成年人表现出严重的临床表型。高死亡率的预测因素与西方人群不同。优化院内治疗并尽量减少治疗延迟为显著改善预后提供了机会。